{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T23:29:21Z","timestamp":1789082961141,"version":"build-2803163510"},"reference-count":20,"publisher":"American Society of Hematology","issue":"5","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,3,11]]},"DOI":"10.1182\/bloodadvances.2024015285","type":"journal-article","created":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T21:00:24Z","timestamp":1736974824000},"page":"1132-1136","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":10,"title":["Nivolumab to restore T-cell fitness in CAR-T refractory multiple myeloma"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5340-1818","authenticated-orcid":false,"given":"Johannes M.","family":"Waldschmidt","sequence":"first","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"},{"name":"2Harvard Medical School, Boston, MA"},{"name":"3Broad Institute of MIT and Harvard, Cambridge, MA"},{"name":"4Department of Internal Medicine II, University Hospital of W\u00fcrzburg, W\u00fcrzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noori","family":"Sotudeh","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"},{"name":"2Harvard Medical School, Boston, MA"},{"name":"3Broad Institute of MIT and Harvard, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8162-4119","authenticated-orcid":false,"given":"Sankalp","family":"Arora","sequence":"additional","affiliation":[{"name":"5Department of Hematology\/Oncology, Center for Multiple Myeloma, Massachussetts General Hospital, Boston, MA"},{"name":"6Department of Hematology, MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tushara","family":"Vijaykumar","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"},{"name":"2Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praveen","family":"Anand","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"},{"name":"2Harvard Medical School, Boston, MA"},{"name":"3Broad Institute of MIT and Harvard, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Stuart","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"},{"name":"2Harvard Medical School, Boston, MA"},{"name":"3Broad Institute of MIT and Harvard, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4380-9673","authenticated-orcid":false,"given":"Julia","family":"Frede","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"},{"name":"2Harvard Medical School, Boston, MA"},{"name":"3Broad Institute of MIT and Harvard, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Campbell","sequence":"additional","affiliation":[{"name":"7Bristol Myers Squibb, Princeton, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shari M.","family":"Kaiser","sequence":"additional","affiliation":[{"name":"7Bristol Myers Squibb, Princeton, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xirong","family":"Zheng","sequence":"additional","affiliation":[{"name":"7Bristol Myers Squibb, Princeton, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil C.","family":"Munshi","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"},{"name":"2Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth C.","family":"Anderson","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"},{"name":"2Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermann","family":"Einsele","sequence":"additional","affiliation":[{"name":"4Department of Internal Medicine II, University Hospital of W\u00fcrzburg, W\u00fcrzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3623-7491","authenticated-orcid":false,"given":"Andrew J.","family":"Yee","sequence":"additional","affiliation":[{"name":"5Department of Hematology\/Oncology, Center for Multiple Myeloma, Massachussetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8040-0535","authenticated-orcid":false,"given":"Birgit","family":"Knoechel","sequence":"additional","affiliation":[{"name":"2Harvard Medical School, Boston, MA"},{"name":"3Broad Institute of MIT and Harvard, Cambridge, MA"},{"name":"8Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens G.","family":"Lohr","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"},{"name":"2Harvard Medical School, Boston, MA"},{"name":"3Broad Institute of MIT and Harvard, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noopur S.","family":"Raje","sequence":"additional","affiliation":[{"name":"2Harvard Medical School, Boston, MA"},{"name":"5Department of Hematology\/Oncology, Center for Multiple Myeloma, Massachussetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,2,28]]},"reference":[{"issue":"8","key":"2025032513474921100_bib1","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed\u00a0and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"10297","key":"2025032513474921100_bib2","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"issue":"11","key":"2025032513474921100_bib3","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"2025032513474921100_bib4","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"2025032513474921100_bib5","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1172\/JCI126397","article-title":"B\u00a0cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma","volume":"129","author":"Cohen","year":"2019","journal-title":"J\u00a0Clin Invest"},{"issue":"4","key":"2025032513474921100_bib6","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.ccell.2023.02.008","article-title":"The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients","volume":"41","author":"Friedrich","year":"2023","journal-title":"Cancer Cell"},{"issue":"7","key":"2025032513474921100_bib7","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1182\/bloodadvances.2023011225","article-title":"CD8 effector T cells enhance response in BCMA-exposed and -na\u00efve multiple myeloma","volume":"8","author":"Firestone","year":"2023","journal-title":"Blood Adv"},{"issue":"18","key":"2025032513474921100_bib8","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"2025032513474921100_bib9","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.tcb.2019.07.002","article-title":"Regulatory mechanisms of inhibitory immune checkpoint receptors expression","volume":"29","author":"Curdy","year":"2019","journal-title":"Trends Cell Biol"},{"issue":"5","key":"2025032513474921100_bib10","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.immuni.2020.04.014","article-title":"Developmental relationships of four exhausted CD8+ T cell subsets reveals underlying transcriptional and epigenetic landscape control mechanisms","volume":"52","author":"Beltra","year":"2020","journal-title":"Immunity"},{"issue":"57","key":"2025032513474921100_bib11","doi-asserted-by":"crossref","first-page":"eabd4344","DOI":"10.1126\/sciimmunol.abd4344","article-title":"A\u00a0cross-talk between CAR T cell subsets and the tumor microenvironment is essential for sustained cytotoxic activity","volume":"6","author":"Boulch","year":"2021","journal-title":"Sci Immunol"},{"key":"2025032513474921100_bib12","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.coi.2021.02.010","article-title":"Mechanisms of response and resistance to CAR T cell therapies","volume":"69","author":"Berger","year":"2021","journal-title":"Curr Opin Immunol"},{"issue":"9","key":"2025032513474921100_bib13","doi-asserted-by":"crossref","first-page":"e459","DOI":"10.1016\/S2352-3026(19)30110-3","article-title":"Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial","volume":"6","author":"Mateos","year":"2019","journal-title":"Lancet Haematol"},{"issue":"9","key":"2025032513474921100_bib14","doi-asserted-by":"crossref","first-page":"e448","DOI":"10.1016\/S2352-3026(19)30109-7","article-title":"Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial","volume":"6","author":"Usmani","year":"2019","journal-title":"Lancet Haematol"},{"key":"2025032513474921100_bib15","unstructured":"US Food and Drug Administration\n          . FDA alerts healthcare professionals and oncology clinical investigators about two clinical trials on hold evaluating KEYTRUDA (pembrolizumab) in patients with multiple myeloma. Accessed 31 October 2024. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-alerts-healthcare-professionals-and-oncology-clinical-investigators-about-two-clinical-trials."},{"issue":"6","key":"2025032513474921100_bib16","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1158\/2643-3230.BCD-22-0018","article-title":"Changes in bone marrow tumor and immune cells correlate with durability of remissions following BCMA CAR T therapy in myeloma","volume":"3","author":"Dhodapkar","year":"2022","journal-title":"Blood Cancer Discov"},{"issue":"4","key":"2025032513474921100_bib17","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1111\/bjh.17397","article-title":"B-cell maturation antigen chimeric\u00a0antigen receptor T-cell re-expansion in a patient with myeloma following salvage programmed cell death protein 1 inhibitor-based combination therapy","volume":"193","author":"Bernabei","year":"2021","journal-title":"Br J Haematol"},{"issue":"4","key":"2025032513474921100_bib18","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/s41591-021-01245-5","article-title":"Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma","volume":"27","author":"Da Vi\u00e0","year":"2021","journal-title":"Nat Med"},{"issue":"1","key":"2025032513474921100_bib19","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/s41467-021-21177-5","article-title":"Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma","volume":"12","author":"Samur","year":"2021","journal-title":"Nat Commun"},{"issue":"22","key":"2025032513474921100_bib20","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1200\/JCO.2018.77.8084","article-title":"T\u00a0cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma","volume":"36","author":"Brudno","year":"2018","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/5\/1132\/2357679\/blooda_adv-2024-015285-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/5\/1132\/2357679\/blooda_adv-2024-015285-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:33:40Z","timestamp":1742949220000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/5\/1132\/535110\/Nivolumab-to-restore-T-cell-fitness-in-CAR-T"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,28]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,3,11]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024015285","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,28]]}}}